Search Results

Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical-stage drug programs, announced that the Japan Patent Office has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma’s drug candidate LP-284.

Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical-stage drug programs, announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024.

Lantern Pharma Inc. today announced that it will host its first quarter 2024 financial results webcast on Thursday, May 9, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Lantern Pharma Inc. announced today that – the company has received regulatory approval to expand its Harmonic™ trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer.

Lantern Pharma Inc. announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications.

Lantern Pharma Inc. announced an important milestone in its antibody-drug conjugate program.

Lantern Pharma Launches “ Webinar Wednesdays ” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development.

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023.

Lantern Pharma today announced the dosing of the first two patients in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-284 in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL) and other high-grade B-cell lymphomas (HGBL) as well as other select solid tumors and sarcomas.

Lantern Pharma’s A.I. Platform, RADR ® Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines.